Heterogeneity in pragmatic randomised trials: sources and management.
Cluster randomised trials
Heterogeneity
Pragmatic randomised trials
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
28 10 2022
28 10 2022
Historique:
received:
25
03
2022
accepted:
14
09
2022
entrez:
28
10
2022
pubmed:
29
10
2022
medline:
1
11
2022
Statut:
epublish
Résumé
Pragmatic trials aim to generate evidence to directly inform patient, caregiver and health-system manager policies and decisions. Heterogeneity in patient characteristics contributes to heterogeneity in their response to the intervention. However, there are many other sources of heterogeneity in outcomes. Based on the expertise and judgements of the authors, we identify different sources of clinical and methodological heterogeneity, which translate into heterogeneity in patient responses-some we consider as desirable and some as undesirable. For each of them, we discuss and, using real-world trial examples, illustrate how heterogeneity should be managed over the whole course of the trial. Heterogeneity in centres and patients should be welcomed rather than limited. Interventions can be flexible or tailored and control interventions are expected to reflect usual care, avoiding use of a placebo. Co-interventions should be allowed; adherence should not be enforced. All these elements introduce heterogeneity in interventions (experimental or control), which has to be welcomed because it mimics reality. Outcomes should be objective and possibly routinely collected; standardised assessment, blinding and adjudication should be avoided as much as possible because this is not how assessment would be done outside a trial setting. The statistical analysis strategy must be guided by the objective to inform decision-making, thus favouring the intention-to-treat principle. Pragmatic trials should consider including process analyses to inform an understanding of the trial results. Needed data to conduct these analyses should be collected unobtrusively. Finally, ethical principles must be respected, even though this may seem to conflict with goals of pragmatism; consent procedures could be incorporated in the flow of care.
Sections du résumé
BACKGROUND
Pragmatic trials aim to generate evidence to directly inform patient, caregiver and health-system manager policies and decisions. Heterogeneity in patient characteristics contributes to heterogeneity in their response to the intervention. However, there are many other sources of heterogeneity in outcomes. Based on the expertise and judgements of the authors, we identify different sources of clinical and methodological heterogeneity, which translate into heterogeneity in patient responses-some we consider as desirable and some as undesirable. For each of them, we discuss and, using real-world trial examples, illustrate how heterogeneity should be managed over the whole course of the trial.
MAIN TEXT
Heterogeneity in centres and patients should be welcomed rather than limited. Interventions can be flexible or tailored and control interventions are expected to reflect usual care, avoiding use of a placebo. Co-interventions should be allowed; adherence should not be enforced. All these elements introduce heterogeneity in interventions (experimental or control), which has to be welcomed because it mimics reality. Outcomes should be objective and possibly routinely collected; standardised assessment, blinding and adjudication should be avoided as much as possible because this is not how assessment would be done outside a trial setting. The statistical analysis strategy must be guided by the objective to inform decision-making, thus favouring the intention-to-treat principle. Pragmatic trials should consider including process analyses to inform an understanding of the trial results. Needed data to conduct these analyses should be collected unobtrusively. Finally, ethical principles must be respected, even though this may seem to conflict with goals of pragmatism; consent procedures could be incorporated in the flow of care.
Identifiants
pubmed: 36303153
doi: 10.1186/s12916-022-02569-w
pii: 10.1186/s12916-022-02569-w
pmc: PMC9615398
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
372Subventions
Organisme : NIA NIH HHS
ID : U54 AG063546
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Int J Epidemiol. 2006 Oct;35(5):1292-300
pubmed: 16943232
N Engl J Med. 2014 Feb 20;370(8):769-72
pubmed: 24552326
J Chronic Dis. 1967 Aug;20(8):637-48
pubmed: 4860352
BMJ. 2004 Jun 26;328(7455):1561-3
pubmed: 15217878
J Am Coll Cardiol. 2018 Dec 18;72(24):3098-3109
pubmed: 30545448
BMJ. 2015 Sep 04;351:h4672
pubmed: 26341898
BMJ. 1996 Dec 7;313(7070):1445-9
pubmed: 8973233
BMJ. 2008 Nov 11;337:a2390
pubmed: 19001484
Cochrane Database Syst Rev. 2015 Apr 29;(4):CD005470
pubmed: 25923419
PLoS Med. 2012;9(11):e1001346
pubmed: 23185138
CMAJ. 2006 Aug 15;175(4):347
pubmed: 16908892
BMJ. 2001 Feb 10;322(7282):355-7
pubmed: 11159665
BMC Med. 2018 Apr 3;16(1):49
pubmed: 29615035
Lancet. 2005 Jan 8-14;365(9454):176-86
pubmed: 15639301
N Engl J Med. 2017 Dec 21;377(25):2445-2455
pubmed: 29081267
Clin Trials. 2005;2(2):152-62
pubmed: 16279137
Lancet. 2010 Feb 20;375(9715):632-3
pubmed: 20198725
J Clin Epidemiol. 2017 Oct;90:99-107
pubmed: 28502810
J Am Soc Nephrol. 2019 May;30(5):890-903
pubmed: 31000566
BMC Med Res Methodol. 2003 Dec 22;3:28
pubmed: 14690550
Trials. 2017 Jun 8;18(1):266
pubmed: 28595589
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
N Engl J Med. 2017 Oct 5;377(14):1391-1398
pubmed: 28976864
N Engl J Med. 2013 Oct 24;369(17):1587-97
pubmed: 23991656
Stat Med. 2012 Feb 20;31(4):328-40
pubmed: 22139891
Lancet. 2020 Jan 4;395(10217):42-52
pubmed: 31839279
J Clin Oncol. 2010 Jan 10;28(2):215-21
pubmed: 19933919
J Clin Epidemiol. 2022 Aug 18;151:113-121
pubmed: 35987403
BMJ. 2001 Jul 7;323(7303):42-6
pubmed: 11440947
Clin Trials. 2015 Oct;12(5):530-6
pubmed: 26374679
Ann Intern Med. 2012 Sep 18;157(6):429-38
pubmed: 22945832
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
JAMA. 2007 Mar 21;297(11):1233-40
pubmed: 17374817
Ann Intern Med. 2001 Jul 17;135(2):112-23
pubmed: 11453711
J Clin Epidemiol. 2017 Nov;91:13-22
pubmed: 28716504
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
J Clin Epidemiol. 2003 Aug;56(8):717-20
pubmed: 12954462
J Clin Epidemiol. 1999 Jan;52(1):19-26
pubmed: 9973070
Trials. 2013 Apr 27;14:115
pubmed: 23782862
Lancet. 2019 Jun 29;393(10191):2613-2623
pubmed: 31128924
Lancet. 2011 Nov 19;378(9805):1788-95
pubmed: 22000683
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Lancet. 2018 Jan 13;391(10116):133-143
pubmed: 29128300
Health Technol Assess. 2013 May;17(18):1-281
pubmed: 23632142
PLoS Med. 2009 Sep;6(9):e1000111
pubmed: 19787044
Australas Med J. 2016 Feb 29;9(2):33-9
pubmed: 26989449
Stat Med. 2000 Oct 15;19(19):2689-97
pubmed: 10986542
J Clin Epidemiol. 2017 Aug;88:7-13
pubmed: 28549929
J Clin Epidemiol. 2011 Dec;64(12):1325-30
pubmed: 21937195
BMJ. 2009 Jan 14;338:a3147
pubmed: 19147478
Paediatr Anaesth. 2019 Jan;29(1):51-58
pubmed: 30375133
BMJ. 2009 Oct 09;339:b4006
pubmed: 19819928
PLoS Med. 2013;10(9):e1001518
pubmed: 24086114
BMJ. 2009 Aug 21;339:b2900
pubmed: 19700507
BMJ. 2015 May 08;350:h2147
pubmed: 25956159